This website uses cookies to ensure you get the best experience on our website. Learn more
Since its inception, the ICS has long been involved in most important mouse functional genomics programmes funded by the European commission.
These large scale EU programs covered :
INFRAFRONTIER2020 project exploited all these emerging ressources to create this current consortium which aims to organize two complementary and linked infrastructure networks for large-scale comprehensive phenotyping and archiving of mouse models serving the European genetics and biomedical research community for the benefit of human health. the ICS stays a major partner in the INFRAFRONTIER2020.
Furthermore, the ICS was or is currently involved in some European projects with a high impact of human public health (Eugene-2, EVGN, GENCODYS, AgedBrainSYSBIO, INTERREG, CanPathPro ...). In 2019 ICS's experts have been integrated in 3 new research programs and partnerships: EarlyCause, GO-DS21 and PATHBIO. For this purpose, ICS provides its mouse biology expertise in generating and characterizing various mouse models.
The project belongs to the second Joint Transnational Call (JTC2020), launched bt the EJP RD co-funded with the European Commission to fund multilateral “Pre-Clinical Research to Develop Effective Therapies for Rare Diseases”. The project MECPer-3D targets Personalized MECP2 gene therapy using CRISPR/Cas9 technology coupled
to AAV-mediated delivery in 3D cell culture and KI mice
EarlyCause (Causative mechanisms & integrative models linking early-life-stress to psycho-cardio-metabolic multi-morbiditywill) identify and demonstrate causative mechanisms and
molecular pathways linking early life stress (ELS) to depression and two
of its main physical comorbidities, namely coronary heart disease and
diabetes. The consortium will disentangle the complex biological
contributions from four key interconnected domains linked to ELS, namely
epigenetics, inflammation, neuroendocrine system, and microbiome.
Furthermore, modifying effects of environmental factors such as
sex/gender, socioeconomics, lifestyle and behavior will be quantified,
thus uncovering potential intervention targets that may reverse the
causative mechanisms and reduce the impact of ELS on multi-morbidity
development in high-risk individuals.
An international group of scientists from 6 countries bring together their expertise to develop a combined experimental and systems
biology platform for predictive modelling of cancer signaling. The EU Horizon 2020 funded project, co-ordinated by Alacris Theranostics GmbH, Berlin, will run for 5 years with a budget of almost 11 million euros.
PHENOMIN-ICS is involved in the CanPathPro project with respect to the generation of genetically modified mouse models of cancer.
CanPathPro brings together the complex molecular data from the "omics" technologies (genomics, transcriptomics and proteomics) that explain the basis of cancers and also reflects their heterogeneity for most, and the mathematical tools of systems biology to visualize and predict signaling pathways for new preclinical, clinical and biotechnology applications.
A long-term direct benefit for cancer patients.
Read the Press Release 2016
CanPathPro Flyer 2017 (807.0 KB)
Last event: INCOME2018
Last news: PHENOMIN-ICS has been nominated for Innovation Radar Prize 2018 in the Excellent science categorie !Final answer for the top 4 innovators in each category on 4-6 december 2018.
All the genetic material our body requires to make all its proteins is located on 23 paired chromosomes. They contain the code for all the proteins our body makes. All cells carry the entire code, but specific cells express specific proteins according to their functions. Down's syndrome, also known as trisomy-21, is a genetic disorder in which a person has three copies of chromosome 21 instead of the usual two. It is associated with a high risk of both severe obesity and intellectual disorder. On the hypothesis that the locus may be on chromosome 21, the EU-funded GO-DS21 project is investigating the genetic mechanisms of this comorbidity "Gene overdosage and comorbidities during the early lifetime in Down Syndrome". Outcomes should benefit patients with Down's syndrome and the general population.
The European infrastructure for phenotyping and archiving of model
mammalian genomes INFRAFRONTIER runs the EU-funded projects INFRAFRONTIER-I3 and InfraCoMP and is a key partner in the EU project BioMedBridges and the International Mouse Phenotyping Consortium (IMPC). The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER
GmbH, includes 3 SMEs and is strategically responding to the INFRADEV3
call with aligned objectives to advance the long-term sustainability
which are 1) development of business models and a stable legal framework; 2) raise awareness of the INFRAFRONTIER Research Infrastructure; 3) provide bespoke services aligned with user demands; 4) promote best practices in mouse phenogenomics; 5) enhance robustness of the INFRAFRONTIER IT infrastructure and use of the EMMA strain resource; and 6) improve business processes.
The INFRAFRONTIER GmbH was created as a non-profit organization to coordinate the transnational activities of the INFRAFRONTIER Research Infrastructure. It is seated in Germany at the Helmholtz Zentrum München. The establishment of the INFRAFRONTIER GmbH is based on a Memorandum of Understanding signed by Germany, France, Czech Republic, Finland, Greece and the European Molecular Biology Laboratory (EMBL).
_1.png)
The INFRAFRONTIER GmbH was established on 11 April 2013 in Munich. The Managing Directors of the INFRAFRONTIER GmbH are Prof. Martin Hrabé de Angelis and Dr. Daniel Lahne of the Helmholtz Zentrum München. The INFRAFRONTIER Council, the representation of all the INFRAFRONTIER GmbH Members, is chaired by Prof. Yann Hérault, director of the ICS and representative of the CNRS. Prof. Radislav Sedlacek, representative of the Institute of Molecular Genetics, is Vice-Chair of the Council.
IPAD-MD project (Research Infrastructure for Phenotyping, Arching and Distribution of Mouse Diseases Models) addresses the global cooperation and coordination between INFRAFRONTIER and complementary research infrastructures world-wide, contributing to the global effort of IMPC.
IPAD-MD focuses on key stakeholder involvement. IPAD-MD has received funding from European Union's Horizon 2020 research and innovation programme under Grant Agreement number 653961
To further develop and exploit the emerging mouse mutant resource, mouse models must be preserved and made available to the European biomedical research community.
To this effect, the EC FP7 funded INFRAFRONTIER-I3 project brings together the European Mouse Mutant Archive (EMMA) network and the leading European centers for systemic phenotyping of mouse mutants. The INFRAFRONTIER-I3 partners aim to meet the future challenges presented by phenotyping, archiving and disseminating mouse models in the European Research Area. The comprehensive physical and data resources that will be generated by INFRAFRONTIER-I3 will contribute to link basic biomedical research to medical applications and thereby drive innovation and support the Europe 2020 Strategy.
EUCOMM Tools for Functional Annotation of the Mouse Genome
European regional development fund (ERDF) and European social fund (ESF), also known as structural funds, as part of the economic, social and territorial cohesion policy;
INTERREG IV Rhin superieur
Genetic and Epigenetic Networks in Cognitive Dysfunction
Gencodys
INFRACoMP's main objective is to coordinate collaboration between the INFRAFRONTIER Research Infrastructure and the International Mouse Phenotyping Consortium (IMPC). To this end, INFRACoMP organizes regular workshops that address the central issues that need to be resolved to ensure a fruitful cooperation between the two initiatives that minimizes redundancy, maximizes mutual benefit and leverages the expertise and infrastructure capacity. INFRACoMP is funded by the EC FP7 Capacities Specific Programme, Grant Agreement number 284501.
European Mouse Mutant Archive: Archiving and distribution of mouse models
EMMA
European Conditional Mouse Mutagenesis Program
EUCOMM
European Mouse Disease Clinic: A distributed phenotyping resource for studying human disease.
EUMODIC
Coordination of resources for conditional expression of mutated mouse alleles
Coordination and Sustainability of International Mouse Informatics Resources CASIMIR, a coordination action of the 6th Framework Programme of the European Commission, will focus on co-ordination and integration of databases set up in support of FP5 and FP6 projects containing experimental data, including sequences, and material resources such as biological collections, relevant to the use of the mouse as a model organism for human disease.
European Network on Functional Genomics of Type 2 Diabetes
EUGENE2
European Vascular Genomics Network
EVGN
RNA Interference Technology as Human Therapeutic Tool
RIGHT
A Transcriptome Atlas Database for Mouse Embryo
Understanding Human Disease through Mouse Genetics
EMTRAIN will establish a pan-European platform for education and training covering the whole lifecycle of medicines
from basic research through clinical development to pharmaco-vigilance. The public consortium consists of the six pan-European biomedical research infrastructures from the ESFRI roadmap that cover a broad spectrum of competencies from molecules to humans, with a pan-European dimension. The EFPIA consortium has considerable experience in training and education, management, pan-European geographical outreach, and an extensive external network of contacts.
EMTRAIN: European Medicines Research Training Network.
System biology of pathways involving brain aging
AgedBrainSYSBIO is a research program which combines integrative systems biology and comparative genomics for studying human brain ageing and most common age-related diseases with a special emphasis on LOAD, for identifying and validating new molecular targets and biomarkers.
